uniQure Announces Q2 2026 Results: Regulatory Progress, Strong Pipeline Updates, and Extended Cash Runway
Key Highlights for Investors
- AMT-130 for Huntington’s Disease: U.S. and U.K. regulatory submissions on track for Q3 2026; four-year Phase I/II data expected in September 2026.
- AMT-260 for Refractory Mesial Temporal Lobe Epilepsy: Early signals of efficacy and a favorable safety profile in initial cohort.
- AMT-191 for Fabry Disease: Promising dose-dependent enzyme activity; manageable safety; dosing paused in some cohorts for safety review.
- Financial Strength: \$259M raised in follow-on offering, cash runway into 2030, and cash position of \$810.3M as of June 30, 2026.
- Potential Share Price Movers: Accelerated approval pathway for AMT-130, strong pipeline progress, and significant capital raise.
Detailed Company Update
Regulatory and Pipeline Progress
uniQure N.V. (NASDAQ: QURE) reported a defining second quarter that could be transformational for both the company and the Huntington’s disease community. The company confirmed, following a productive Type B meeting with the FDA, that it remains on track to submit a Biologics License Application (BLA) for AMT-130 in Q3 2026 under the accelerated approval pathway. The FDA has agreed that a BLA submission based on current clinical data is reasonable, but requires alignment on the confirmatory study design before submission. Notably, the FDA suggested a randomized standard-of-care control design (rather than a sham procedure) and expects the confirmatory study to be well underway or possibly fully enrolled at the time of accelerated approval. Discussions with the FDA on confirmatory study design are ongoing, and uniQure plans to start the study swiftly after finalizing the design.
Additionally, a pre-submission meeting with the UK’s MHRA went well, and the company is on track for a Q3 2026 regulatory submission in the UK as well. Crucially, uniQure plans to present topline four-year data from the Phase I/II AMT-130 study in September 2026, which will include follow-up on all 24 patients across both high and low dose cohorts.
Pipeline Updates
-
AMT-260 (Refractory Mesial Temporal Lobe Epilepsy):
- Preliminary six-month data from the first (low dose) cohort showed three of six patients had reductions in disabling seizures ranging from 79% to 100% during months 4-6. The other three showed changes from a 33% decrease to a 36% increase.
- No serious adverse events related to AMT-260 or surgery were reported. All adverse events were mild or moderate (mainly headaches), with no immunosuppression required.
- Second dose cohort enrollment expected to complete in Q3 2026; updated results expected in the first half of 2027.
-
AMT-191 (Fabry Disease):
- New data from the Phase I/II study demonstrated dose-dependent increases in α-Gal A enzyme activity, with up to 229.6-fold above normal at mid dose and up to 143.6-fold at the highest dose.
- Plasma lyso-Gb3 levels remained stable, and all 11 dosed patients were withdrawn from enzyme replacement therapy.
- The safety profile remains manageable overall, though dosing in mid- and high-dose cohorts is paused due to asymptomatic liver enzyme elevations (dose-limiting toxicities in two patients, resolved with immunosuppression).
Financial Highlights
- Cash Position: \$810.3 million in cash, cash equivalents, and current investment securities as of June 30, 2026, versus \$622.5 million at year-end 2025. The company’s resources are expected to fund operations through 2030.
- Capital Raise: Upsized public offering in June 2026 raised gross proceeds of \$259 million at \$45.50 per share (5.69 million shares).
-
Q2 2026 Financial Results:
- Revenue: \$5.8 million (up from \$5.3 million Q2 2025, mainly due to higher license revenue).
- R&D Expenses: \$34.0 million (down \$1.4 million YoY due to lower facility and personnel costs, offset by increased spend on AMT-260, AMT-162, and AMT-191 programs).
- SG&A Expenses: \$17.4 million (up \$3.9 million YoY due to higher staffing, IP fees, and IT costs, partially offset by lower professional fees).
- Other Expense: \$8.0 million (up from \$2.2 million, mostly due to Hemgenix supply costs).
- Non-operating Items: \$27.0 million net expense (versus \$6.6 million gain in Q2 2025), driven by \$20.4 million negative currency swing and \$16 million loss on pre-funded warrant liabilities.
- Net Loss: \$81.1 million, or \$1.22 per share (versus \$37.7 million, or \$0.69 per share, in Q2 2025).
Upcoming Catalysts
- Topline four-year data readout for AMT-130 in September 2026—a potentially pivotal event for the share price.
- BLA submissions for AMT-130 in both the U.S. and U.K. expected in Q3 2026.
- Completion of Phase I/IIa AMT-260 second cohort enrollment in Q3 2026, with updated data due in H1 2027.
- Participation in key investor events, including the 2026 Biotech Summer Summit (August 10-12, Newport, RI).
What Investors Should Watch
- Accelerated Approval Pathway for AMT-130: FDA’s openness to an accelerated approval BLA is a major milestone. Shareholders should closely watch ongoing discussions regarding the confirmatory study design and the timing of data releases, as these could drive significant valuation changes.
- Clinical Data Readouts: The September 2026 AMT-130 four-year data and ongoing pipeline results are key catalysts for share price movement.
- Financial Position: The company’s extended cash runway through 2030 enhances operational security and supports continued pipeline investment and potential commercial launches.
- Risks and Uncertainties: Investors should be aware of the standard risks, including regulatory uncertainty, trial results, post-approval requirements, and ongoing safety events (e.g., AMT-191 liver enzyme elevations).
Disclaimer
This article is for informational purposes only and is not investment advice. All forward-looking statements are subject to risks and uncertainties, including clinical, regulatory, and market risks, which could cause actual results to differ materially. Investors should review uniQure’s filings with the SEC and consult with financial advisors before making investment decisions.
